SUNNYVALE, Calif., Aug. 3, 2026
Ceribell, Inc. has secured a significant reimbursement milestone after the U.S. Centers for Medicare & Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for its FDA-cleared Delirium Monitor System, strengthening access to advanced neurological monitoring for hospitalized Medicare patients. Effective Oct. 1, 2026, eligible hospitals may receive up to $2,171 in additional reimbursement per Medicare patient case using the company’s breakthrough technology. The decision follows the December 2025 FDA 510(k) clearance of the Ceribell Delirium Monitor System, the first and only FDA-cleared device designed to aid delirium screening and continuous monitoring. Integrated into the company’s point-of-care EEG platform, the system uses artificial intelligence (AI) to continuously analyze electroencephalogram (EEG) signals and automatically alert clinicians when brain activity patterns associated with delirium are detected. The CMS approval represents a major commercial milestone by supporting broader hospital adoption of rapid bedside neurological monitoring, helping clinicians diagnose and manage critically ill patients more efficiently while improving access to innovative brain monitoring technologies.
CMS NTAP Expands Access to Advanced Point-of-Care Brain Monitoring
The newly awarded CMS NTAP reinforces the clinical value of Ceribell’s innovative neurological platform by providing hospitals with additional reimbursement for adopting cutting-edge technology that addresses unmet needs in critical care. The Ceribell Point-of-Care EEG System combines delirium monitoring with the company’s previously FDA-cleared capabilities for detecting nonconvulsive seizures and electrographic status epilepticus (ESE) within a single bedside platform. Rather than relying on separate diagnostic systems, healthcare providers can simultaneously monitor multiple neurological conditions using one portable device that delivers rapid, objective brain assessments. Continuous AI-assisted EEG analysis enables earlier recognition of neurological deterioration, potentially supporting faster clinical intervention for patients in intensive care units and emergency departments. By reducing barriers to reimbursement, the CMS decision is expected to encourage broader implementation of advanced EEG technology across U.S. hospitals while strengthening patient access to timely neurological evaluation.
AI-Powered EEG Technology Supports Faster Clinical Decision-Making
The Ceribell Delirium Monitor System leverages proprietary AI-powered algorithms to continuously evaluate EEG data in real time, notifying clinicians when brain activity patterns suggest delirium. This capability provides objective neurological information that can support faster treatment decisions for critically ill patients, where early recognition of brain dysfunction is essential. Company leadership described the CMS determination as validation of both the clinical importance and healthcare value of point-of-care EEG technology. According to Jane Chao, Ph.D., Co-founder and Chief Executive Officer of Ceribell, the reimbursement decision represents an important milestone in expanding commercial access to the company’s innovation while advancing its long-term vision of establishing EEG as a new neurological vital sign in acute-care medicine. The additional reimbursement also strengthens the commercial pathway for hospitals seeking to integrate AI-enabled neurological monitoring into routine patient care without requiring multiple diagnostic devices.
Advertisement
Ceribell Strengthens Commercial Position Following FDA Clearance
The CMS reimbursement decision further enhances Ceribell’s commercial momentum following the FDA 510(k) clearance of its Delirium Monitor System and reinforces the company’s position within the rapidly growing medical technology sector. By combining portable EEG hardware, AI-driven analytics, and continuous bedside monitoring into one integrated platform, Ceribell continues to address critical gaps in neurological diagnosis and management across emergency rooms and intensive care units. Beginning Oct. 1, 2026, the NTAP is expected to improve hospital adoption by offsetting the cost of implementing this innovative technology for eligible Medicare patients. As healthcare providers increasingly prioritize rapid neurological assessment, Ceribell’s integrated seizure and delirium monitoring platform is positioned to support improved clinical workflows, expand access to advanced brain monitoring, and accelerate the use of AI-enabled diagnostics in acute-care settings.
Source: Ceribell press release
